NRG-LU001

Closed to Accrual

Return to Protocol Table

Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC

Principal Investigator

Theos Tsakiridis, MD

Status

Closed to Accrual

Date Opened To Accrual

August 25 2014

Date Closed to Accrual

December 15 2016

Disease Site

Lung [LU]

Non-small Cell Lung Cancer

Phase

Developmental Therapeutics

Primary Objective

To determine whether MET added to chemoradiotherapy can improve progression-free survival (PFS) in patients with locally advanced NSCLC

Patient Population

Pathologically proven diagnosis of Stage IIIA or IIIB non-small cell lung cancer; patients must have unresectable disease, are medically inoperable, or are not willing to undergo surgical management.

Target Accrual

168

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Blank CRFs

NRG-LU001 Blank Forms.pdf

Forms

Regulatory Resources

Study Memos

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.